Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 10:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 148 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Lipid-lowering therapy Clear all
Recruiting Not applicable Interventional

Aggressive Lipid Lowering Therapy in ICI-Treated Melanoma

NCT07704918
View directory record Official record
Conditions
Melanoma
Interventions
Statins (atorvastatin, rosuvastatin, simvastatin, or pravastatin), +/- ezetimibe, +/- PCSK9 inhibitor (alirocumab, evolocumab, inclisiran)
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
55 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 6, 2026, 10:22 AM EDT
Completed Phase 4 Interventional Results available

Lipid Management in Renal Transplant Recipients Using Evolocumab.

NCT04608474
View directory record Official record
Conditions
Hyperlipidemias
Interventions
Evolocumab
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 6, 2026, 10:22 AM EDT
Completed Phase 3 Interventional

Clevidipine in the Perioperative Treatment of Hypertension (ECLIPSE-NTG)

NCT00093886
View directory record Official record
Conditions
Hypertension
Interventions
clevidipine, nitroglycerin
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
629 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
28
States / cities
Birmingham, Alabama • Montgomery, Alabama • Tucson, Arizona + 19 more
Source: ClinicalTrials.gov public record
Updated May 6, 2014 · Synced Oct 6, 2026, 10:22 AM EDT
Completed Phase 3 Interventional

Clevidipine in the Perioperative Treatment of Hypertension (ECLISPE-SNP)

NCT00093912
View directory record Official record
Conditions
Hypertension
Interventions
clevidipine, sodium nitroprusside
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
739 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
29
States / cities
Birmingham, Alabama • Montgomery, Alabama • Burbank, California + 22 more
Source: ClinicalTrials.gov public record
Updated May 6, 2014 · Synced Oct 6, 2026, 10:22 AM EDT
Completed Phase 3 Interventional Results available

Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects

NCT02207634
View directory record Official record
Conditions
Dyslipidemia
Interventions
Evolocumab, Placebo, Background Statin Therapy
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
40 Years to 85 Years
Enrollment
1,974 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
134
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 123 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2018 · Synced Oct 6, 2026, 10:22 AM EDT
Completed Not applicable Interventional Results available

Study Comparing 3 Different Treatments for Arthritis of the Lower Back (Lumbar Spinal Stenosis)

NCT01943435
View directory record Official record
Conditions
Lumbar Spinal Stenosis
Interventions
NSAIDs; adjunctive analgesics; adjunctive anti-depressants, Lumbar epidural injection, Joint Mobilizations (spine, sacroiliac, hip), Individualized exercises: clinical setting, Group Exercise: community setting
Drug · Procedure · Other
Lead sponsor
Michael Schneider, DC, PhD
Other
Eligibility
60 Years and older
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 2, 2018 · Synced Oct 6, 2026, 10:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Pharmacokinetics and Pharmacodynamics of LGT209 in Healthy Volunteers With Elevated Cholesterol and in Hypercholesterolemic Patients Treated With Statins

NCT01859455
View directory record Official record
Conditions
Hypercholesterolemia, LDL Cholesterol
Interventions
LGT209 50 mg, LGT209 300 mg, Placebo, Statins (atorvastatin or simvastatin)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Fort Myers, Florida • Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 6, 2026, 10:22 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Stop Retinal Ganglion Cell Dysfunction Study

NCT02390284
View directory record Official record
Conditions
Glaucoma
Interventions
Latanoprost, Bimatoprost, Travoprost, Timolol, Dorzolamide, Brinzolamide, Acetazolamide, Methazolamide
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 85 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Oct 6, 2026, 10:22 AM EDT
Completed Phase 4 Interventional Results available

Steroid Free Immunosuppression in Liver Transplantation

NCT00296244
View directory record Official record
Conditions
Liver Cirrhosis, Liver Transplant Disorder
Interventions
Steroids, Basiliximab, Tacrolimus, Enteric-coated Mycophenolic acid (EC-MPA)
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 72 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 19, 2012 · Synced Oct 6, 2026, 10:22 AM EDT
Terminated Phase 3 Interventional

Efficacy of Lapaquistat Acetate Co-Administered With Current Lipid-Lowering Treatment on Blood Cholesterol Levels in Subjects With Homozygous Familial Hypercholesterolemia

NCT00263081
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Lapaquistat acetate and current lipid-lowering treatment, Current lipid-lowering treatment
Drug
Lead sponsor
Takeda
Industry
Eligibility
8 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Cincinnati, Ohio • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 24, 2012 · Synced Oct 6, 2026, 10:22 AM EDT
Completed Not applicable Interventional Results available

International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA)

NCT01471522
View directory record Official record
Conditions
Cardiovascular Diseases, Coronary Disease, Coronary Artery Disease, Heart Diseases, Myocardial Ischemia
Interventions
cardiac catheterization, coronary artery bypass graft surgery, percutaneous coronary intervention, Lifestyle, Medication
Procedure · Behavioral · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years and older
Enrollment
5,179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
109
States / cities
Birmingham, Alabama • Yuma, Arizona • Beverly Hills, California + 82 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2023 · Synced Oct 6, 2026, 10:22 AM EDT
Completed Phase 2 Interventional Results available

Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer

NCT00723099
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, Chronic Myelogenous Leukemia, Chronic Phase Chronic Myelogenous Leukemia, Indolent Non-Hodgkin Lymphoma, Lymphoma, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Recurrent Chronic Lymphocytic Leukemia, Recurrent Follicular Lymphoma, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Small Lymphocytic Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Chronic Myelogenous Leukemia, Refractory Follicular Lymphoma, Refractory Hodgkin Lymphoma, Refractory Lymphoplasmacytic Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Small Lymphocytic Lymphoma, T-Cell Non-Hodgkin Lymphoma
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cyclosporine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Total-Body Irradiation, Umbilical Cord Blood Transplantation
Procedure · Drug · Other + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 69 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
6
States / cities
Aurora, Colorado • Denver, Colorado • Salt Lake City, Utah + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2019 · Synced Oct 6, 2026, 10:22 AM EDT
Recruiting Phase 2 Interventional

Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis

NCT03844061
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
Belimumab, Rituximab, Placebo Subcutaneous Injection, Placebo Infusion, MMF
Drug · Other
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 6, 2026, 10:22 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Immunonutrition for Diabetic Foot Ulcers

NCT05281562
View directory record Official record
Conditions
Diabetes Mellitus, Diabetic Peripheral Neuropathy, Diabetic Foot Ulcer
Interventions
Lovaza, L-Arginine Powder, Vitamin C
Drug
Lead sponsor
Prisma Health-Midlands
Other
Eligibility
18 Years to 99 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 6, 2026, 10:22 AM EDT
Withdrawn Not applicable Interventional

Omega 3 Supplementation and Ocular Surface Disease in Glaucoma

NCT01630551
View directory record Official record
Conditions
Ocular Surface Disease
Interventions
Fishoil supplement, Olive Oil
Dietary Supplement
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Oct 6, 2026, 10:22 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

NCT00245037
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Precancerous Condition
Interventions
therapeutic allogeneic lymphocytes, busulfan, cyclosporine, fludarabine phosphate, mycophenolate mofetil, peripheral blood stem cell transplantation, Total Body Irradiation (TBI), Granulocyte colony-stimulating factor (G-CSF), Phenytoin, Methotrexate
Biological · Drug · Procedure + 1 more
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 27, 2017 · Synced Oct 6, 2026, 10:22 AM EDT
Completed Phase 4 Interventional Results available

Statin Therapy for Ischemic and Nonischemic Cardiomyopathy

NCT00701220
View directory record Official record
Conditions
Cardiovascular Disease, Cardiomyopathy, Heart Disease, Myocardial Disease, Myocardial Ischemia
Interventions
Atorvastatin Calcium
Drug
Lead sponsor
Philip Binkley
Other
Eligibility
18 Years to 85 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Oct 6, 2026, 10:22 AM EDT
Completed Phase 4 Interventional Results available

Evaluate Carotid Artery Plaque Composition by Magnetic Resonance Imaging in People Receiving Cholesterol Medication

NCT00715273
View directory record Official record
Conditions
Coronary Artery Disease, Carotid Artery Diseases, Atherosclerosis
Interventions
Atorvastatin, Niacin, Colesevelam, Placebo Niacin, Placebo Colesevelam
Drug
Lead sponsor
University of Washington
Other
Eligibility
21 Years to 70 Years
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2019
U.S. locations
4
States / cities
Los Angeles, California • Boise, Idaho • Seattle, Washington + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2022 · Synced Oct 6, 2026, 10:22 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Efficacy and Safety of LIB003 in HeFH Patients on Oral Lipid Therapy Needing Further LDL-C Reduction

NCT04797104
View directory record Official record
Conditions
Heterozygous Familial Hypercholesterolemia
Interventions
lerodalcibep
Drug
Lead sponsor
LIB Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 6, 2026, 10:22 AM EDT
Enrolling by invitation Phase 3 Interventional

Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C Reduction

NCT04798430
View directory record Official record
Conditions
Cardiovascular Disease With Mention of Arteriosclerosis, Elevated Cholesterol, Familial Hypercholesterolemia
Interventions
lerodalcibep
Drug
Lead sponsor
LIB Therapeutics LLC
Industry
Eligibility
10 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
4
States / cities
Evanston, Illinois • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Oct 6, 2026, 10:22 AM EDT
Completed Not applicable Interventional

Vitamin D and Microbiota in Cystic Fibrosis

NCT02589444
View directory record Official record
Conditions
Vitamin D Deficiency, Cystic Fibrosis
Interventions
High-Dose Vitamin D3, Stool Sample, Sputum Sample, Sham Comparator, Blood draw
Dietary Supplement · Other · Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 6, 2026, 10:22 AM EDT
Completed Phase 3 Interventional Results available

Plaque Regression and Progenitor Cell Mobilization With Intensive Lipid Elimination Regimen (PREMIER), Phase I

NCT01004406
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
intensive LDL-lowering therapy, standard statin monotherapy
Device · Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
31 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Oklahoma City, Oklahoma • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Oct 6, 2026, 10:22 AM EDT
Completed No phase listed Observational

Patient and Provider Assessment of Lipid Management Registry

NCT02341664
View directory record Official record
Conditions
Hyperlipidemia, Hypercholesterolemia, Cardiovascular Disease, Diabetes, Chronic Kidney Disease (CKD), Hypertension, Smoking, Myocardial Infarction (MI), Unstable Angina, Angina, Coronary Artery Disease (CAD), Stroke, Transient Ischemic Attack (TIA), Carotid Stenosis, Peripheral Arterial Disease, Atherosclerosis, Claudication
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
7,658 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
14
States / cities
Little Rock, Arkansas • San Pedro, California • Ventura, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Oct 6, 2026, 10:22 AM EDT
Terminated Phase 2 Interventional

Implitapide in Patients With Homozygous Familial Hypercholesterolemia (HoFH) on Maximal Concurrent Lipid-Lowering Therapy

NCT00079846
View directory record Official record
Conditions
Familial Hypercholesterolemia
Interventions
Implitapide
Drug
Lead sponsor
Medical Research Laboratories International
Industry
Eligibility
8 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 6, 2026, 10:22 AM EDT